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INTRODUCTION
Dyslipidaemia is always present in the nephrotic syndrome, together with oedemas, proteinuria and hypoalbuminaemia. Moreover, the presence of hyperlipidaemia may worsen the prognosis of the nephrotic syndrome and favour progression to renal insufficiency. It is for this reason that, during the last decade, treatments proposed for the dyslipidaemia, which accompanies this syndrome, include dietary manipulation, 1 adrenocorticotropic hormone (ACTH), 2 and especially statins, whether they be lovastatin, [3] [4] [5] sinvastatin, 6 pravastatin, 7 or fluvastatin. 8 Atorvastatin is a potent inhibitor of 3-hydroxymethylglutaryl-CoA reductase, which reduces low density lipoprotein (LDL) cholesterol and triglycerides in a dose-dependent manner, and is widely used in hypercholesterolaemia and combined hyperlipidaemia. 9 In addition, it has been shown that 10 mg of atorvastatin improved the lipid profile of renal transplant patients who did not respond to other statins. 10 The aim of this study was to determine the efficacy of atorvastatin in controlling dyslipidaemia associated with the nephrotic syndrome, and assess its safety profile.
METHODS

Patients
Ten ambulatory patients with a clinical and laboratory diagnosis of nephrotic syndrome with an evolution of more than 1 year (oedemas, 24 h proteinuria > 3.5 g and albuminaemia < 30 g/L), with slight deterioration in renal function (creatinine clearance 62 ± 33 mL/min), were studied by the Nephrology Service of the University Clinical Hospital, Malaga, Spain. All patients had combined dyslipidaemia and none had received treatment with lipid-lowering agents. Informed consent was obtained before patient inclusion in the present study, which was approved by the hospital Investigation and Ethics Committee. A 12-h fasting blood sample was taken from all patients at baseline, and at 3 and 6 months after starting treatment with 10 mg atorvastatin nightly. The patients were advised to follow a diet low in salt, cholesterol and saturated fats.
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Clinical data
The clinical characteristics of the patients are shown in Table 1 . Measurements were taken of weight, height, and of systolic and diastolic P Valdivielso et al.
blood pressures at each visit. Body composition was measured by using bioelectrical impedance analysis, as described, 12 using a Holtain BCA (Holtain LTD, Crosswell, Dyfed Wales, UK). During the study period, the doses of angiotensin-converting enzyme inhibitors, hypotensive agents and immunosupressants remained unchanged.
Laboratory data
The following were measured at baseline, and at 3 and 6 months after starting therapy: serum levels of urea, creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ -glutamyl transpeptidase, creatine phosphokinase (CPK) and albumin, as well as proteins in a 24-h urine collection by using a Cobas Integra autoanalyser with commercial reagents (Roche, Basel, Switzerland). Antithrombin III activity was measured in citrated plasma by using a chromogenic method (Dade Behring AG, Düdingen, France), and the levels of fibrinogen were measured with the Claus coagulometric method (Dade Behring AG); both measurements took place in a Sysmex Ca-6000 autoanalyser (Dade Behring). Lipids and lipoproteins were analysed in plasma obtained in tubes containing ethylenediaminetetraacetic acid potassium (EDTA-K 3 ). The lipoproteins were separated following a modified version of the routine method of the Lipid Research Clinic: the very low density lipoprotein (VLDL) was separated after centrifuging the plasma at 100 000 g at density (d) = 1.006 g/mL for 18 h at 10 ° C; after aspirating the supernatant (VLDL), the infranatant (LDL + HDL) was subjected to a double precipitation with heparin-manganese chloride and dextran, enabling the determination of the concentrations of HDL2 and HDL3 cholesterol. 13 The LDL cholesterol was calculated by subtracting the concentration of HDL cholesterol from the VLDL infranatant. The cholesterol and the triglycerides in plasma and lipoprotein fractions were quantified by enzymatic assays, using commercial reagents from Roche, in a Cobas Mira autoanalyser (Hoffman La Roche Ltd, Basel, Switzerland). To prevent the interference of the Mn 2 Cl used to separate the HDL with the enzymatic reaction, a solution of 8 mmol/L EDTA-K3 was added. 14 
Statistical analysis
Modifications during the study period of the different parameters were evaluated by using an analysis of variance, using the procedure of the General Lineal Model for repeated measures. Calculations were performed by using SPSS 10.0.6 (SPSS Inc., Chicago, IL, USA), and P < 0.05 was considered significant.
RESULTS
The medication was well tolerated and the patients complied with more than 80% of the treatment schedule. Table 2 summarizes the variations in the lipids and lipid fractions 3 and 6 months after starting treatment; the ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; CPK, creatine phosphokinase; GGT, γ -glutamyl transpeptidase. * P < 0.05. addition of 10 mg atorvastatin was followed by mean reductions after 3 and 6 months in LDL cholesterol (36 and 41%, respectively), total cholesterol (27 and 31%, respectively) and plasma triglycerides (22 and 31%, respectively). These important changes in plasma lipids were not accompanied by significant changes in weight or body composition; they were measured as total body water, or as systolic or diastolic blood pressure readings (Table 3) . Not correlation between changes in plasma lipid parameters and changes in proteinuria over time were found.
There were no adverse effects involving treatment compliance. Safety profile data (Table 3) showed a significant increase in creatine phosphokinase (CK) levels only, although in no case was this increase above the upper limit of normal, and therefore, this finding is irrelevant from the clinical point of view.
Renal function, measured by serum levels of urea and creatinine (Table 3 ) remained stable throughout the study period, although the mean proteinuria levels fell in all patients by > 1 g/24 h ( P < 0.05).
DISCUSSION
This paper shows the effects of atorvastatin in patients with nephrotic syndrome. Regarding its lipid lowering efficacy, 3 and 6 months after its introduction, atorvastatin significantly reduced levels of total cholesterol, LDL cholesterol and plasma triglycerides, which agrees with the efficacy of this statin in patients with polygenic hypercholesterolaemia and combined hyperlipidaemia. 15 This reduction is even more important because other factors such as diabetes and the taking of steroids could have contributed to the dyslipidaemia in these patients. It is interesting to note that there was a 15% rise in the levels of HDL cholesterol, although this was not significant. This discrete increase in HDL cholesterol occurred at the expense of the HDL2 subfraction, which might be related with protection against coronary heart disease. However, this small increase does not support other observations that associate high doses of atorvastatin with a reduction in HDL cholesterol. No adverse events occurred to require the suspension of treatment or modification of the dose, and compliance was good in all 10 patients.
With regards to the laboratory measurements, the levels of transaminases remained stable, and the levels of creatine phosphokinase (CPK) rose significantly, although there was no one case that rose above the upper limit of normal, which indicates that the increase was of no clinical importance. The nephrotic syndrome is a procoagulant state, often complicated by venous thrombosis 16 and, therefore, it is important to emphasize this at the doses used and over the study period; the serum levels of fibrinogen and the antithrombin-III activity were not affected by the treatment. This is of particular interest because fibrinogen is known to be a risk factor for cardiovascular disease 17 and because its levels may increase in hyperlipidaemic patients taking high doses of atorvastatin, 18 although not at the more usual dose of 10 mg used in the present study, and which has even been reported to reduce fibrinogen. 19 Renal function remained stable throughout the 6-month study period, but these results should be read with caution as the present study was not designed to evaluate the effects of atorvastatin on renal function and proteinuria, and the follow-up period involved was short. However, of note is the fact that the proteinuria levels decreased in all except one patient by an average of more than 1 g/day. This significant reduction in proteinuria was unrelated to changes in the concomitant intake of a protein-reducing medication, with doses of angiotensinconverting enzyme inhibitors and other hypotensive and immunosupresant agents remaining unchanged in all patients. Studies with other statins have shown either a significant reduction 4 or no change 3 in the proteinuria, although the conviction exists that reducing the levels of circulating lipoproteins improves glomerular lesions and protects the kidney from a worsening renal function. 20, 21 Although atorvastatin has been shown to prevent glomerulosclerosis in rabbits made hypercholesterolemic by a high cholesterol diet, 22 a spontaneous improvement of the nephrosis in our patients cannot be ruled out. In fact, kinetic studies in nephrotic patients indicate that the hyperlipidaemia, rather than being a result of a defect in LDL clearance, is a consequence of the overproduction of LDL-apoB, which disappears with the spontaneous recovery from nephrosis. 23 In conclusion, treatment with 10 mg atorvastatin in a small group of heterogeneous patients with nephrosis was accompanied by a significant reduction in total cholesterol, predominantly because of a significant decline in LDL-cholesterol and reduction in triglycerides. There were no adverse effects. The improvement in nephrosis seen within this group over time is a confounding factor upon the lipid changes, which may reflect a spontaneous resolution of nephrosis, or it could be an independent effect of atorvastatin. This question remains to be confirmed by larger controlled studies.
